Jerkeman, M <br/><br/>
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.  [electronic resource] 

 -  Annals of hematology  Jul 2004 
 - 414-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0939-5555 
<br/><br/><label>Standard No.: </label>10.1007/s00277-004-0855-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily B, Member 1--analysis<br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Biomarkers<br/>Bleomycin--administration & dosage<br/>Cohort Studies<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Ki-67 Antigen--analysis<br/>Leucovorin--administration & dosage<br/>Life Tables<br/>Lymphoma, Large B-Cell, Diffuse--chemistry<br/>Male<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Neoplasm Proteins--analysis<br/>Neoplastic Stem Cells--chemistry<br/>Norway--epidemiology<br/>Prednisone--administration & dosage<br/>Prognosis<br/>Proto-Oncogene Proteins c-bcl-2--analysis<br/>Risk Factors<br/>Survival Analysis<br/>Sweden--epidemiology<br/>Treatment Outcome<br/>Tumor Suppressor Protein p53--analysis<br/>Vincristine--administration & dosage